Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB503237015

Publication Date:

March 22, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline.
Highlights
The global Glioblastoma Multiforme (GBM) Therapeutics market was valued at US$ 602.4 million in 2022 and is anticipated to reach US$ 996.4 million by 2029, witnessing a CAGR of 8.8% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North America dominated the global market in 2017, accounting for over 35% share in terms of revenue. Europe was anOthers major market for glioblastoma multiforme (GBM) therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Glioblastoma Multiforme (GBM) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Glioblastoma Multiforme (GBM) Therapeutics.
The Glioblastoma Multiforme (GBM) Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Glioblastoma Multiforme (GBM) Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Glioblastoma Multiforme (GBM) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva Pharmaceutical
Emcure Pharmaceuticals
Segment by Type
ChemOthersapy
Targeted Drug Therapy
Radiation Therapy
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Glioblastoma Multiforme (GBM) Therapeutics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 ChemOthersapy
1.2.3 Targeted Drug Therapy
1.2.4 Radiation Therapy
1.3 麻豆原创 by Application
1.3.1 Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Glioblastoma Multiforme (GBM) Therapeutics Growth Trends by Region
2.2.1 Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Glioblastoma Multiforme (GBM) Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Glioblastoma Multiforme (GBM) Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Dynamics
2.3.1 Glioblastoma Multiforme (GBM) Therapeutics Industry Trends
2.3.2 Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Drivers
2.3.3 Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Challenges
2.3.4 Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue
3.1.1 Global Top Glioblastoma Multiforme (GBM) Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Glioblastoma Multiforme (GBM) Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Glioblastoma Multiforme (GBM) Therapeutics Revenue
3.4 Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Glioblastoma Multiforme (GBM) Therapeutics Revenue in 2022
3.5 Glioblastoma Multiforme (GBM) Therapeutics Key Players Head office and Area Served
3.6 Key Players Glioblastoma Multiforme (GBM) Therapeutics Product Solution and Service
3.7 Date of Enter into Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Type
4.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Glioblastoma Multiforme (GBM) Therapeutics Breakdown Data by Application
5.1 Global Glioblastoma Multiforme (GBM) Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Glioblastoma Multiforme (GBM) Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Glioblastoma Multiforme (GBM) Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.1.4 Merck Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.1.5 Merck Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.2.4 Roche Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.2.5 Roche Recent Development
11.3 Arbor Pharmaceuticals
11.3.1 Arbor Pharmaceuticals Company Detail
11.3.2 Arbor Pharmaceuticals Business Overview
11.3.3 Arbor Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.3.4 Arbor Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.3.5 Arbor Pharmaceuticals Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.4.4 Pfizer Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.4.5 Pfizer Recent Development
11.5 AbbVie
11.5.1 AbbVie Company Detail
11.5.2 AbbVie Business Overview
11.5.3 AbbVie Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.5.4 AbbVie Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.5.5 AbbVie Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.6.4 Amgen Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.6.5 Amgen Recent Development
11.7 Bristol-Myers Squibb
11.7.1 Bristol-Myers Squibb Company Detail
11.7.2 Bristol-Myers Squibb Business Overview
11.7.3 Bristol-Myers Squibb Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.7.4 Bristol-Myers Squibb Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.7.5 Bristol-Myers Squibb Recent Development
11.8 Sun Pharmaceuticals
11.8.1 Sun Pharmaceuticals Company Detail
11.8.2 Sun Pharmaceuticals Business Overview
11.8.3 Sun Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.8.4 Sun Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.8.5 Sun Pharmaceuticals Recent Development
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Company Detail
11.9.2 Teva Pharmaceutical Business Overview
11.9.3 Teva Pharmaceutical Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.9.4 Teva Pharmaceutical Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.9.5 Teva Pharmaceutical Recent Development
11.10 Emcure Pharmaceuticals
11.10.1 Emcure Pharmaceuticals Company Detail
11.10.2 Emcure Pharmaceuticals Business Overview
11.10.3 Emcure Pharmaceuticals Glioblastoma Multiforme (GBM) Therapeutics Introduction
11.10.4 Emcure Pharmaceuticals Revenue in Glioblastoma Multiforme (GBM) Therapeutics Business (2018-2023)
11.10.5 Emcure Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Merck
Roche
Arbor Pharmaceuticals
Pfizer
AbbVie
Amgen
Bristol-Myers Squibb
Sun Pharmaceuticals
Teva Pharmaceutical
Emcure Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.